FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1624-1625 October 13, 2005 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Viable Mycobacterium bovis bacille Calmette–Guérin (BCG) is one of the most widely used vaccines to control tuberculosis. Administered as a single shot to newborns, it prevents severe disease and reduces mortality among children, but it does not protect against pulmonary tuberculosis in children or adults. With 9 million new, mostly pulmonary cases and nearly 2 million deaths from tuberculosis each year, there is a great need for improved vaccines against this devastating disease. A new study of vaccine efficacy by Grode and colleagues¹ therefore comes as welcome news.

The immune response to mycobacteria relies predominantly on T-cell immunity, rather than . . . [Full Text of this Article]

Source Information

From the Public Health Research Institute, International Center for Public Health, Newark, N.J.

This article has been cited by other articles:

• Irwin, S. M., Goodyear, A., Keyser, A., Christensen, R., Troudt, J. M., Taylor, J. L., Bohsali, A., Briken, V., Izzo, A. A. (2008). Immune Response Induced by Three Mycobacterium bovis BCG Substrains with Diverse Regions of Deletion in a C57BL/6 Mouse Model. CVI 15: 750-756 [Abstract] [Full Text]  
• Scheindlin, S. (2006). The Fight Against Tuberculosis. Mol. Interv. 6: 124-130 [Full Text]